admin – Page 7532 – Get News Story

In Vitro Toxicology Testing Market Worth $17.1 billion | MarketsandMarkets

“Key players in the in vitro toxicology testing market include Thermo Fisher Scientific Inc. (US), Merck KGaA (Germany), Eurofins Scientific (Luxembourg), Laboratory Corporation of America Holdings (US), Charles River Laboratories (US)”

In Vitro Toxicology Testing Market in terms of revenue was estimated to be worth $10.8 billion in 2023 and is poised to reach $17.1 billion by 2029, growing at a CAGR of 9.5% from 2023 to 2029

In Vitro Toxicology Testing Market in terms of revenue was estimated to be worth $10.8 billion in 2023 and is poised to reach $17.1 billion by 2029, growing at a CAGR of 9.5% from 2023 to 2029 according to a new report by MarketsandMarkets. Technological advancements taking place in assays and equipment being used for such studies, along with the increasing R&D expenditure to undertake toxicity studies during the early stages of drug development, are also aiding the adoption of in vitro testing. Stringent regulations have also been implemented across large parts of the globe to minimize animal testing, which has prompted the pharmaceutical and cosmetics industries to shift to in vitro methods for product testing. However, authorities are still reluctant to fully accept safety and efficacy data generated from non-animal methods, which is a major restraint to market growth.

Download an Illustrative overview: https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=209577065

The consumables segment accounted for the largest share by product & service in the In vitro toxicology testing market in 2022.

By product and service, the In vitro toxicology testing market has been further categorized as consumables, assays, equipment, software, and services. Consumables accounted for the largest share of the in vitro toxicology testing market in 2022. The large share of this segment can be attributed to the increasing demand for high-quality reagents and the repeated use of media and reagents in in vitro toxicology studies. Additionally, the growing R&D activities in the pharmaceutical industry and the increased initiatives by governments in various countries to strengthen their product safety assessment capabilities are supporting the growth of this market.

The organ toxicity segment is expected to grow at a higher rate during the forecast period.

Based on the toxicity endpoints and tests, the in vitro toxicology testing market has been segmented into absorption, distribution, metabolism, and excretion (ADME), skin irritation, corrosion, and sensitization, genotoxicity, cytotoxicity, ocular toxicity, organ toxicity, phototoxicity, dermal toxicity, and other toxicity endpoints & tests. In 2022, the ADME segment accounted for the largest share of the in vitro toxicology testing market. However, the organ toxicity segment is expected to grow at a higher growth rate during the forecast period of 2023-2028. This can be attributed to increasing regulatory demands for safety assessment and reducing animal testing, continuous advancements in cell culture and tissue engineering technologies, and increasing drug development needs.

The pharmaceutical & biopharmaceutical segment accounted for the largest share of the industry segment in the in vitro toxicology testing market in 2022.

Based on industry, the in vitro toxicology testing market has been segmented into pharmaceutical & biopharmaceutical, consumer care, food, and other industries (including chemical and medical device industries). In 2022, the pharmaceutical & biopharmaceutical industry segment accounted for the largest share of the in vitro toxicology testing market. One of the major factors driving the growth of this segment is the mandate of preclinical safety assessment for the marketing approval of pharmaceutical products. Additionally, the rising investments in discovering new ways to construct molecules to study genetics and proteins and the increasing focus on reducing economic losses due to drug failures in the late stage are expected to increase the demand for in vitro tests to screen potentially toxic molecules during drug development.

The cell culture technologies segment accounted for the largest share of the technologies segment in the in vitro toxicology testing market in 2022.

Based on the technologies, the in vitro toxicology testing market has been segmented into cell culture, high-throughput screening, and toxicogenomics. In 2022, cell culture technologies accounted for the largest share. This can be attributed to the fact that it is the most preferred technique for toxicity testing owing to its capability of mimicking in vivo conditions. Cell and tissue-based technologies are commonly employed for in vitro toxicology testing in pharmacology. Cell cultures, either bacterial or mammalian, can express the same genes and proteins as their in vivo counterparts. Their ability to produce similar testing environments is one of the major factors driving the growth of this segment.

The Europe region catered for the largest share of the in vitro toxicology testing market in 2022.

The in vitro toxicology testing market is segmented into North America, Europe, the Asia Pacific (APAC), Latin America (LATAM), and the Middle East and Africa (MEA). The European region is witnessing increasing investments to develop biologics and advanced dosage forms, with the impending patent expiration of several blockbuster drugs. The need to reduce the time and cost incurred to bring a drug to market—roughly 10 to 12 years, has contributed to the demand for in vitro toxicology testing of drugs.

Request Sample Pages: https://www.marketsandmarkets.com/requestsampleNew.asp?id=209577065

Key Market Players of In Vitro Toxicology Testing Industry:

Key players in the in vitro toxicology testing market include Thermo Fisher Scientific Inc. (US), Merck KGaA (Germany), Eurofins Scientific (Luxembourg), Laboratory Corporation of America Holdings (US), Charles River Laboratories (US), SGS SA (Switzerland), Bio-Rad Laboratories, Inc. (US), Evotec SE (Germany), Promega Corporation (US), Catalent, Inc. (US), Agilent Technologies, Inc. (US), Intertek Group plc (UK), Revvity (US), Inotiv (US), BioIVT (US), Lonza (Switzerland), Creative Biolabs (US), Shanghai Medicilon Inc. (China), Creative Bioarray (US), Aragen Life Sciences Ltd. (India), Enzo Biochem Inc. (US), Microbac Laboratories, Inc. (US), Vimta Labs Ltd. (India), Pacific BioLabs Inc. (US), and MB Research Laboratories (US).

Recent Developments:

In March 2023, Agilent Technologies, Inc. (US) acquired e-MSion (US). Through this acquisition, Agilent will integrate the e-MSion’s ExD cell into its portfolio of advanced workflows, instruments, and analytical solutions for biotherapeutic characterization and development.
In January 2023, Eurofins Scientific expanded its presence in India with the establishment of a new, fully equipped, state-of-the-art laboratory campus in Genome Valley, Hyderabad. The lab will support pharma and biotech companies in the areas of synthetic organic chemistry, analytical R&D, bioanalytical services, in vivo pharmacology, safety toxicology, and formulation R&D.

Get 10% Free Customization on this Report: https://www.marketsandmarkets.com/requestCustomizationNew.asp?id=209577065

Media Contact
Company Name: MarketsandMarkets™ Research Private Ltd.
Contact Person: Mr. Aashish Mehra
Email: Send Email
Phone: 18886006441
Address:630 Dundee Road Suite 430
City: Northbrook
State: IL 60062
Country: United States
Website: https://www.marketsandmarkets.com/Market-Reports/in-vitro-toxicology-testing-market-209577065.html

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: In Vitro Toxicology Testing Market Worth $17.1 billion | MarketsandMarkets

Zen Millionaire Ken Honda Exposes the Money Mindset that May Be Holding People Back on ‘Tiger Therapy’ Podcast

““There’s this limiting belief that once you think about money a certain way — like money has to be earned by working hard for your job — you will be bound by money beliefs, and then that determines how much money we have and how much money we make.” – Ken Honda”

Philosopher, businessman, and best-selling personal development author Ken Honda explores why we feel embarrassed about our spending, how to make peace with money, and how he overcame disappointment to achieve success.

“Tiger Therapy,” the acclaimed and insightful podcast produced by knowledge infrastructure solution Tigerhall, welcomes “Zen Millionaire” Ken Honda, Japan’s best-selling personal development author. Honda’s books, which are brimming over with fresh insights on finances and how they affect our happiness and potential, have sold more than 8 million copies.

Honda dives into the podcast by explaining the difference between “money IQ” and “money EQ,” explaining why both are important facets of our understanding of money.

“A lot of people are in a fighting mode,” Honda explains. “Your attitude is like a warrior. No matter how much money you make, you can’t be satisfied. You have to be satisfied and also find peace with money. Otherwise, the first million will make you feel like you are not enough, so you’ll want to make a second million and a third million and a first billion, and a second billion. There is no end to it.”

Honda also unpacks the idea of “happy money,” explaining how our feelings about money and earning can profoundly impact how we express ourselves and engage with those around us. Those who feel they must fight for their money in the business world can bring home feelings of frustration and anger that darken the mood of their homes and disrupt the harmony in their relationships.

“Happy money,” earned in peace, results in a happier life, Honda explains. “Happy money makes you more gentle, more generous, and a happy, kind person,” he says. “When you are dealing with happy money, after coming home, you bring in happiness and appreciation. So your dinner table will have lots of laughter and fun.”

The shame that can often surround spending is another topic Honda dissects. Sharing how we spend with others can make us feel uncomfortable and vulnerable as if our privacy has been invaded, he remarks.

Honda goes on to explain that when our spending is seen as irresponsible, it can lead to us feeling incapable and worthless as a person. He advises that healing our money wounds is essential to overcoming our limiting feelings about money. His advice is not to see money as a measurement of our self-worth.

The messaging we get about money from a young age is another topic Honda explores on the “Tiger Therapy” podcast. He recounts how his father taught him that money has two faces — one an angel and one a devil — explaining that money can bring out the best or the worst of us.

“With money, people can be so terrifying…[even] violent. With money, people can be very kind and loving,” Honda says. “If you have kids, I want you to teach them that money can be both very angelic and money can be very devilish because it brings out the worst and the best part of us.”

The heart of Tiger Therapy is exploring self-doubt and limiting beliefs — a topic Honda says appeared in his life when his first book did not enjoy immediate success. “I had this vision that my book would come out and become number one, and then I would instantly become a national best-selling author,” Honda shares. “I wrote the book. It didn’t happen.”

Honda’s response to the feelings of disappointment and self-doubt was to press on and believe in his vision.

“If I had stopped somewhere in between, I would now be a former writer, but since I believed in my vision, I kept on going, and it happened,” Honda says. “Success and money will follow you after a certain time. It’s always like that, so don’t get depressed, even if it doesn’t bring you instant success. It doesn’t happen that way.”

To listen to Honda’s episode of “Tiger Therapy” and learn more about the podcast, visit this link.

Ken Honda

Money and happiness expert Ken Honda is a best-selling self-development author in Japan, with book sales surpassing eight million copies since 2001. His latest book is called “Happy Money: The Japanese Art of Making Peace With Your Money.” Ken studied law at Waseda University in Tokyo and entered the Japanese workforce as a business consultant and investor. Ken’s financial expertise comes from owning and managing several businesses, including an accounting company, a management consulting firm, and a venture capital corporation. His writings bridge the topics of finance and self-help, focusing on creating and generating personal wealth and happiness through deeper self-honesty. Ken provides ongoing support through mentoring programs, business seminars, therapeutic workshops, and correspondence courses.

Tigerhall

Tigerhall is a knowledge infrastructure solution where subscribers can access bite-sized business-related content from top experts in their fields. The platform contains over 1,300 pieces of content in the form of podcasts, live streams, courses, and more. Tigerhall’s goal is to make professional development and business education affordable, and level the playing field for people to succeed in business despite outside circumstances, background, or financial situations. In the midst of a recession, and on the back of the COVID-19 pandemic, Tigerhall is making business education affordable and easily accessible. They are pioneering social learning, and changing how businesses engage in professional development. Leading clients include Spotify, HP, and Cisco.

Pippa Woodhead

Pippa Woodhead, Head of Podcasts at Tigerhall, has had her fair share of imposter syndrome moments in her career. This struggle inspired her to create “Tiger Therapy.” Originally from the UK, Pippa has lived in India and Thailand, and now proudly calls Singapore her home. During her five years at Tigerhall, Pippa conducted over 800 interviews with exceptional figures in the business world, including Fortune 500 executives, workplace happiness experts, neuroscientists, and Olympic medalists. She discovered that great leaders are often highly self-aware, recognize their own limiting beliefs, and know when to heed self-doubt as a valuable message — and when to push past it. Through these insightful podcast conversations, Pippa learned a lot about herself, and the medium itself became her form of therapy. With “Tiger Therapy,” she aims to engage in meaningful conversations, explore people’s career journeys, discover more about herself, and share some laughs along the way.

Media Contact
Company Name: OtterPR
Contact Person: Pilar Lewis
Email: Send Email
Address:320 1st Ave N
City: St. Petersburg
State: Florida
Country: United States
Website: OtterPR.com

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Zen Millionaire Ken Honda Exposes the Money Mindset that May Be Holding People Back on ‘Tiger Therapy’ Podcast

Single Use Assemblies Market- Global Forecast to 2028

“North America regional market held a substantial share of the single-use assemblies market owing to the strong presence of the pharmaceutical industry, increased research and development (R&D) spending, the expansion of biosimilars markets, the rising number of drug development projects, and stringent regulations for the pharmaceutical industry.”

Browse 235 market data Tables and 44 Figures spread through 272 Pages and in-depth TOC on “Single Use Assemblies Market by Product (Bag, Filtration, Bottle, Mixing Assemblies), Solution (Standard, Customized), Application (Filtration, Cell Culture, Storage, Sampling, Fill-finish), End User (Biopharma, CROS & CMOS) – Global Forecasts to 2028

Single Use Assemblies Market in terms of revenue was estimated to be worth $2.5 billion in 2023 and is poised to reach $5.2 billion by 2028, growing at a CAGR of 15.6% from 2023 to 2028 according to a new report by MarketsandMarkets™. The global single-use assemblies market is growing owing to factors such as rising adoption of single-use assemblies among startups and SMEs, development and launch of technologically advanced single-use products that offer streamlined workflows, portability, and rapid implementation, and increasing demand for single-use assemblies for R&D and biologics manufacturing. The market growth could be hampered by regulatory concerns and significant concerns regarding extractables and leachables arising from the components of single-use assemblies in bioproduction.

Download an Illustrative overview: https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=46226549

The bag assemblies segment accounted for the largest share by product in the single-use assemblies market in 2022.

By product, the single-use assemblies market has been further categorized as bag assemblies, filtration assemblies, bottle assemblies, mixing system assemblies, and other products. The bag assemblies segment held the largest share of the global single-use assemblies market in 2022. The increasing use of bioprocessing applications is driving the growth of the single-use bag assemblies segment. These bags enable critical liquid handling in biomanufacturing processes and eliminate the time & cost of additional cleaning-in-place and sterilization-in-place (CIP/SIP) system setup, maintenance, and validation.

The standard solutions segment accounted for the largest share of the solution segment in the single-use assemblies market in 2022.

Based on solutions, the global single-use assemblies market has been segmented into standard solutions and customized solutions. The standard solutions segment held the largest market share in 2022. The pharmaceutical and biopharmaceutical industries have adopted standard solutions extensively, driven by the benefits they offer. These advantages encompass enhanced manufacturing process efficiency, lowered capital costs, increased flexibility through the utilization of pre-qualified assembly components, reduced implementation time, and greater adaptability in production planning.

The filtration & purification segment accounted for the largest share of the application segment in the single-use assemblies s market in 2022.

The single-use assemblies market is segmented into filtration & purification, aseptic transfer, cell culture & mixing, formulation & fill-finish, storage, and sampling based on application. Filtration & purification is the largest application segment of the single-use assemblies market. Factors such as cost efficiency, flexibility and scalability, reduced risk of cross-contamination, and technological advancements in single use assemblies used for filtration & purification are expected to drive the filtration & purification segment during the forecast period.

The North American region catered for the largest share of the single-use assemblies market in 2022.

The single-use assemblies market is segmented into North America, Europe, the Asia Pacific (APAC), Latin America (LATAM), and the Middle East and Africa (MEA). North America regional market held a substantial share of the single-use assemblies market owing to the strong presence of the pharmaceutical industry, increased research and development (R&D) spending, the expansion of biosimilars markets, the rising number of drug development projects, and stringent regulations for the pharmaceutical industry.

Request Sample Pages: https://www.marketsandmarkets.com/requestsampleNew.asp?id=46226549

Key Market Players of Antibody Drug Conjugates Industry:

Key players in the single-use assemblies market include Thermo Fisher Scientific Inc. (US), Sartorius AG (Germany), Danaher (US), Merck KGaA (Germany), PARKER HANNIFIN CORP (US), Saint-Gobain (France), Repligen Corporation (US), Corning Incorporated (US), Entegris (US), Meissner Filtration Products, Inc. (US), NewAge Industries (US), Antylia Scientific (US), Lonza (Switzerland), Romynox (Netherlands), SaniSure (US), Keofitt A/S (Denmark), Intellitech, Inc. (US), Dover Corporation (US), Foxx Life Sciences (US), TSE Industries, Inc. (US), Fujimori Kogyo Co., Ltd. (Japan), Michelin (France), Cellexus (Scotland), and Fluid Flow Products, Inc. (US).

Recent Developments:

In February 2022, Sartorius Stedim Biotech (France) acquired the chromatography division of Novasep (France). The portfolio acquired comprises chromatography systems primarily suited for smaller biomolecules.
In August 2022, Thermo Fisher Scientific opened a new single-use technology site in Tennessee, which has 400,000 square feet of floor space. It became the company’s largest SUT site in its growing network.

Get 10% Free Customization on this Report: https://www.marketsandmarkets.com/requestCustomizationNew.asp?id=46226549

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Single Use Assemblies Market- Global Forecast to 2028

HLA Typing for Transplant Market worth $1.1 billion | MarketsandMarkets

“Some of the prominent players in the HLA typing for the transplants market are Thermo Fisher Scientific (US) Illumina, Inc. (US), QIAGEN (Germany), CareDx (US),F. Hoffmann-La Roche Ltd. (Switzerland)”

HLA Typing for Transplant Market in terms of revenue was estimated to be worth $0.8 billion in 2023 and is poised to reach $1.1 billion by 2028, growing at a CAGR of 6.3% from 2023 to 2028 according to a new report by MarketsandMarkets™.

HLA Typing for Transplant Market in terms of revenue was estimated to be worth $0.8 billion in 2023 and is poised to reach $1.1 billion by 2028, growing at a CAGR of 6.3% from 2023 to 2028 according to a new report by MarketsandMarkets™. Factors such as the increasing transplants volume worldwide, rising number of transplant & diagnostic centers, technological advancements, government initiatives to boost HLA typing services, rising public -private investments boost research in HLA genotyping, and increased focus of players to enhance their manufacturing & distribution capabilities across emerging countries are likely to support the growth of HLA typing for transplant market during the forecast period.

Download an Illustrative overview: https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=96374742

Key Market Players of Antibody Drug Conjugates Industry:

Some of the prominent players in the HLA typing for the transplants market are Thermo Fisher Scientific (US) Illumina, Inc. (US), QIAGEN (Germany), CareDx (US),F. Hoffmann-La Roche Ltd. (Switzerland),Bio-Rad Laboratories, Inc. (US), Immucor, Inc. (US), Luminex Corporation (US), TBG Diagnostics Limited. (Australia) FUJIREBIO (Japan),Omixon Inc. (US), GenDX (Netherlands), BAG Diagnostics GmbH (Germany), Creative Biolabs (US), and PacBio (US).

Recent Developments:

In September 2023, Omixon, Inc. (US) launched its NanoTYPE RUO Multiplex Human Leukocyte Antigen Amplification kit compatible with Oxford Nanopore’s MinION Platform.
In November 2022, Illumina, Inc. (US) opened a new state-of-the-art Solutions Center in Dubai for expanding genomics research in Middle East
In March 2022, 021, Immucor, Inc. (US) launched MIA FORA NGS Express HLA Typing Software.

Request Sample Pages: https://www.marketsandmarkets.com/requestsampleNew.asp?id=96374742

Based on the product and service, the reagents & consumables segment held the largest share of the market in 2022.

Based on the product & service, the HLA typing for the transplants market is segmented into software & services, reagents & consumables, instruments. The reagents & consumables segment held the largest share of the global HLA typing for the transplants market in 2022. Growing need for reliable, faster identification of HLA alleles during transplantation is likely to boost the growth of this segment.

Based on technology, the molecular assays segment held the largest share of the market in 2022.

Based on technology, the HLA typing for the transplants market is segmented into molecular assay technologies and non-molecular assay technologies. The molecular assay technology segment captured the largest market share of HLA typing for transplant market by technology. This is attributed the strong adoption of molecular based technology such as NGS and PCR systems for HLA typing among transplant centers, and hospitals and technological and the ability to provide higher resolution HLA typing over serological methods.

Based on the end user, the independent reference laboratories segment accounted for the largest share of this market in 2022.

Based on the end user, the HLA typing for the transplants market is categorized into independent reference laboratories, hospitals & transplant centers , and research laboratories & academic institutes. independent reference laboratories accounted for the largest share of the HLA typing for the transplants market in 2022 owing to the capacity of reference laboratories to process large and volume of sample, presence of expertise performing complex HLA tests and interpreting results offering offering high quality HLA typing services.

North America accounted for the largest share of the HLA typing for transplants market in 2022.

North America accounted for the largest share of the HLA typing for the transplants market in 2022, followed by Europe. The Asia Pacific is estimated to be the fastest-growing regional market for HLA typing for transplants market during the forecast period.

The dominance of North America in HLA typing for transplant market is attributed to the rapid surge in the organ transplantation procedures, strong foothold of players offering transplant diagnostic products (including HLA typing), and rising research collaborations to identify the novel HLA genes and their role in organ transplantation.

Get 10% Free Customization on this Report: https://www.marketsandmarkets.com/requestCustomizationNew.asp?id=96374742

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: HLA Typing for Transplant Market worth $1.1 billion | MarketsandMarkets

Author Shawn Geegbae is Releasing his Latest Romantic Comedy, “12 Days To Love” on Feb 12th

12 Days To Love takes the readers on a cosmic journey of love and laughter, blending romance with the charm of all zodiac signs.

Author Shawn Geegbae’s highly anticipated romantic comedy novel, “12 Days To Love,” will be released on major platforms, including Amazon, on Monday, 12th February 2024. Set in the colorful background of the DC Metro region, the book follows the themes of astrology, humor, and the unpredictable nature of romance.

The book’s plot revolves around the charming Alex Williams, a Washington, DC professional who finds himself love-struck with his company’s new employee, Jennifer Aubrey. While collaborating on a project with Jennifer, Alex felt sparks flying. Their professional relationship grew into friendship and something more until a miscommunication left Alex devastated by their breakup.

Alex’s labors to win Jennifer’s heart lead him to a mysterious psychic offering a magical potion promising irresistibility. Eager to reclaim lost love, Alex drinks the potion, expecting immediate results. Still, in a twist of fate, the psychic’s solution becomes a dilemma, leading him into an unexpected and enchanting journey through all 12 zodiac signs.

From Aries’s fiery passion to Pisces’s thoughtful nature, Alex finds himself stuck in a whirlwind of experiences that challenge his understanding of love and compatibility. The only way out? He must navigate the diverse spectrum of personalities associated with each zodiac sign.

Shawn expresses his gratitude and teases about his upcoming book, “I’m thrilled to share ’12 Days To Love’ with readers. It’s a heartwarming journey through love, laughter, and the quirks of the zodiac. I hope it brings joy and a touch of magic to everyone’s day”.

Shawn Geegbae’s “12 Days To Love” is not just a rom-com; it explores the intricacies of relationships, wrapped in humor and relatable moments. It takes the readers through a journey filled with twists and turns of love, showing that the path to true love is sometimes written in the stars.

Targeting those who are hopeless romantics or skeptics of the stars, Shawn’s brilliant mind will provide an unparalleled storytelling experience, captivating audiences across the globe. He invites readers to laugh, reflect, and believe in the magic of love. Prepare to be enchanted as “12 Days To Love” hits bookshelves on February 12.

Learn more at: https://www.shawngeegbae.com/

About Shawn Geegbae:

Shawn Geegbae is an American author and writer based in Northern Virginia. A finance graduate from Syracuse University and a former commodity broker on Wall Street, Shawn discovered his passion for storytelling. As a Ronald E. McNair Achievement Scholar and a national service fraternity Alpha Phi Omega member, Shawn Geegbae infuses his writing with a unique blend of wit, wisdom, and warmth. His literary works, including “Cupid/Valentino” and “Harry’s Bearded Adventures,” showcase his talent for entertaining and inspiring readers.

Media Contact
Company Name: Shawn Geegbae
Contact Person: Shawn Geegbae
Email: Send Email
City: Fairfax
State: Virginia
Country: United States
Website: www.shawngeegbae.com

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Author Shawn Geegbae is Releasing his Latest Romantic Comedy, \”12 Days To Love\” on Feb 12th

Clinical Trial Supplies Market worth $6.3 billion by 2028

“Asia Pacific is accounted to be the fastest-growing segment of the market. The growth of the clinical trial supplies markets on the region is driven by rising emphasis on strategic initiatives such as partnerships, collaborations & expansion and growing influx of investments in the life sciences sector. Large number of clinical trials in the region is further likely to upsurge the segmental growth.”

Thermo Fisher Scientific Inc. is focuses on inorganic growth strategies to maintain its market position. The company has strong geographic presence in more than 180 countries across North America, Europe, Asia, the Middle East, Africa, and Latin America. Its is more focusing on providing the clinical trial services through it subsidiary Patheon Pharma.

Clinical Trial Supplies Market in terms of revenue was estimated to be worth $3.9 billion in 2023 and is poised to reach $6.3 billion by 2028, growing at a CAGR of 9.9% from 2023 to 2028 according to a new report by MarketsandMarkets™.

The growth of the market is projected to be driven by factors such as collaborations & partnerships among market players for clinical trial outsourcing service, increasing R&D expenditure by biopharmaceutical and pharmaceutical companies and the growing the number of clinical trials conducted across the globe.

Download an Illustrative overview: https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=172240059

The logistics and distribution segment is expected to have the dominant share of the clinical trial supplies market in 2022.

Based on services, the global clinical trial supplies market is segmented into logistics & distribution, storage & retention, packaging, labeling & blinding, manufacturing, comparator sourcing, others services (solutions and ancillary supplies). In 2022, the logistics & distribution segment accounted for largest share of the clinical trial supplies market. The presence of prominent players offering clinical trial services is the driving factor for the growth of the logistics & distribution segment during the forecast period.

The oncology segment accounted for the largest share of the disease type segment in the clinical trial supplies market in 2022.

The oncology segment is the fastest growing segment and accounted for the largest share of the clinical trial supplies market in 2022. The large share of this segment can be attributed to rising demand for cancer medicines subsequently uplifting the number of research for innovative drugs and development and increasing R&D for new drug development by pharmaceutical and biotechnology companies.

The Asia Pacific region is the fastest-growing region of the clinical trial supplies market in 2022.

The Asia Pacific is accounted to be the fastest-growing segment of the market. The growth of the clinical trial supplies markets on the region is driven by rising emphasis on strategic initiatives such as partnerships, collaborations & expansion and growing influx of investments in the life sciences sector. Large number of clinical trials in the region is further likely to upsurge the segmental growth. For instance, according to WHO, around 9,954 clinical trials were registered in India highest in Asia Pacific and global level, China registered around 5,465 leading to third largest in the world.

Request Sample Pages: https://www.marketsandmarkets.com/requestsampleNew.asp?id=172240059

Key Market Players of Antibody Drug Conjugates Industry:

The clinical trial supplies market is consolidated, with a small number of players competing for market shares. Thermo Fisher Scientific Inc. (US), Catalent, Inc. (US), Eurofins Scientific (France), Piramal Pharma Solutions (India), PRA Health Sciences (US), Marken (A Subsidiary of UPS) (US), Parexel International (MA) Corporation (US), Biocair (UK), AlmacGroup (UK), Sharp Services, LLC (US), PCI Pharma Services (US), Nuvisan (Germany), Lonza Group (Switzerland), are some of the leading players in this market. Most companies in the market focus on organic and inorganic growth strategies, such as service launches, expansions, acquisitions, partnerships, agreements, and collaborations, to increase their service offerings, cater to the unmet needs of customers, increase their profitability, and expand their presence in the global market.

Recent Developments:

In July 2023, Thermo Fisher Scientific Inc. (US) has entered into collaboration with the national minority quality forum (NMQF), an independent non-profit dedicated to research and education. This collaboration facilitated through NMQF’s Alliance for Representative Clinical Trials (ARC), aims to improve the inclusion of historically underserved patient groups in clinical research.
In April 2023, Almac Group (UK), has introduced the IXRS®3 Partnership Network, designed to expedite the creation and deployment of advanced eClinical solutions for biopharmaceutical sponsors.
In March 2023, Icon Plc (Ireland) has entered into a strategic partnership with LEO Pharma (Denmark), and This collaboration aims to enhance LEO Pharma’s clinical trial operations, focusing on patient-centricity and cost-efficiency. The goal is to strengthen LEO Pharma’s

Get 10% Free Customization on this Report: https://www.marketsandmarkets.com/requestCustomizationNew.asp?id=172240059

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Clinical Trial Supplies Market worth $6.3 billion by 2028

Cystatin C Assay Market worth $540 million | MarketsandMarkets

“The European cystatin C assay market is segmented into Germany, France, the UK, Italy, Spain, and the Rest of Europe. UK is projected to occupy the highest share during the forecast period.”

The Cystatin C assay industry is poised for significant growth in the near future, driven by a rising demand for accurate and reliable biomarkers in healthcare.

Cystatin C Assay Market in terms of revenue was estimated to be worth $377 million in 2023 and is poised to reach $540 million by 2028, growing at a CAGR of 7.5% from 2023 to 2028 according to a new report by MarketsandMarkets™. The growth of this market is majorly driven by growing number of old age population and rising number of kidney diseases. However, high development costs of cystatin C assay may challenge the growth of this market.

Download an Illustrative overview: https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=186075328

UK in European cystatin C assay market to witness the highest shares during the forecast period.

The European cystatin C assay market is segmented into Germany, France, the UK, Italy, Spain, and the Rest of Europe. UK is projected to occupy the highest share during the forecast period. Market growth is attributed to the rising geriatric population & chronic diseases, increasing number of accredited clinical & hospital laboratories, growing government healthcare expenditure.

Clinical laboratories in End user’ cystatin C assay market to witness the second highest growth rate during the forecast period.

Based on the end user, cystatin C assay market is segmented into hospitals, clinical laboratories, and pharmaceutical & biotechnology companies & CROs & academic research institutes The clinical laboratories registered the second highest CAGR, due to the growing number of clinical tests performed in laboratories and the increasing number of accredited laboratories, and serving as centralized hubs for diagnostic testing, where a wide array of tests, including cystatin C assays which support market growth.

China dominates the Asia Pacific cystatin C assay market.

The APAC cystatin C assay market is segmented into Japan, China, India, and Rest of Apac. In 2022, China accounted for the largest share of the Asian cystatin C assay market. The large share of China can be attributed to the government efforts to increase awareness about the early detection of diseases and regular health check-ups; rising healthcare expenditure; the increasing number of hospitals and clinical diagnostic laboratories in India and China; and strengthening research base for diagnostic procedures across India, China, and Japan, rising cases of CKD.

Request Sample Pages: https://www.marketsandmarkets.com/requestsampleNew.asp?id=186075328

Key Market Players of Antibody Drug Conjugates Industry:

The significant players in the cystatin C assay are Siemens Healthcare GmbH (Germany), Thermo Fisher Scientific Inc. (US), Abbott (US), Roche Diagnostics Limited. (Switzerland), and Bio-Techne (US), Randox Laboratories Ltd. (UK), DiaSys Diagnostic Systems GmbH (Germany), and Eurolyser Diagnostica GmbH (Austria)

Cystatin C Assay Market Dynamics:

Drivers:

Rising prevalence of kidney diseases
Growing geriatric population
Recent advancements in chemiluminescence immunoassay technologies
Growth in biotechnology and biopharmaceutical industries
Increasing adoption of POC testing
Supportive government policies

Restraints:

Stringent requirements for approval of cystatin C assay instruments and consumables
High development costs of cystatin C assays

Opportunities:

Growth opportunities in emerging economies
Importance of companion diagnostics
Development of condition-specific biomarkers and tests

Challenge:

Dearth of skilled professionals

Get 10% Free Customization on this Report: https://www.marketsandmarkets.com/requestCustomizationNew.asp?id=186075328

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Cystatin C Assay Market worth $540 million | MarketsandMarkets

Veterinary Electrosurgery Market worth $120 million by 2028 | Medtronic (Ireland), B. Braun (Germany), Integra LifeSciences (US), Olympus Corporation (Japan), Covetrus, Inc. (US)

“The veterinary electrosurgery market is a consolidated market, the prominent players in the global market include Medtronic (Ireland), B. Braun (Germany), Integra LifeSciences (US), Olympus Corporation (Japan), Covetrus, Inc. (US)”

North America has various advantages—an advanced healthcare system, high public and private healthcare spending, rise in the companion animal population, and the significant presence of prominent players in the region are the major factors contributing to the growth of North America and the largest share of the veterinary electrosurgery market APAC is known to grow at the highest rate.

Veterinary Electrosurgery Market in terms of revenue was estimated to be worth $85 million in 2023 and is poised to reach $120 million by 2028, growing at a CAGR of 7.3% from 2023 to 2028 according to a new report by MarketsandMarkets™. The demand for veterinary electrosurgery is increasing due to a number of factors, including the growing pet population, the increasing awareness of the importance of preventive care, and the rising disposable incomes of pet owners. There have been a number of technological advancements in veterinary electrosurgery in recent years, such as the development of bipolar electrosurgery generators and computer-controlled electrosurgery generators. These advancements have made electrosurgery a more versatile and effective surgical technique. In addition to this, the growing demand for minimally invasive surgical procedures in veterinary medicine is also driving the growth of the veterinary electrosurgery market.

Download an Illustrative overview: https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=141714652

The bipolar electrosurgical instruments devices segment holds the largest market share during the forecast period.

The veterinary electrosurgery market can be generally divided into monopolar instruments, bipolar instruments, and consumables & accessories. The veterinary electrosurgery market by product will be significantly dominated by the segment of bipolar instruments in 2022. Bipolar electrosurgery is a minimally invasive surgical technique that causes less damage to surrounding tissue and results in shorter recovery times for patients. This makes it an ideal choice for a variety of veterinary surgical procedures, such as spaying and neutering, tumor removal, and wound repair.

The general surgery segment is expected to grow at the highest rate during the forecast period.

General surgery, gynecological & urological surgery, dental surgery, orthopedic surgery, ophthalmic surgery, and other applications are the major application segments in which the veterinary electrosurgery market is widely categorized in this study. The veterinary electrosurgery market for general surgery is primarily driven by the increasing demand for precise, minimally invasive surgical procedures in general surgery. Furthermore, technological advancements, such as AI integration and improved safety features, enhance the efficiency and safety of electrosurgical procedures in general surgery.

Request Sample Pages: https://www.marketsandmarkets.com/requestsampleNew.asp?id=141714652

In the end-user segment, veterinary clinics are expected to grow at the highest share in the veterinary electrosurgery market.

According to end users, the veterinary electrosurgery market can be classified into three categories: veterinary hospitals, veterinary clinics and other end users. The end users market in 2022 was dominated by the veterinary clinics. The growing implementation of veterinary electrosurgery technology in pet clinics, in addition to rising technological improvements, are factors contributing to the significant share of the market.

North America will continue to dominate the veterinary electrosurgery market in 2028.

On the basis of region, the veterinary electrosurgery market is segmented into North America, Europe, Asia Pacific, Latin America, the Middle East, and Africa. North America has various advantages—an advanced healthcare system, high public and private healthcare spending, rise in the companion animal population, and the significant presence of prominent players in the region are the major factors contributing to the growth of North America and the largest share of the veterinary electrosurgery market APAC is known to grow at the highest rate. The growth in the market can be attributed to increasing R&D activities, and high growth in the veterinary healthcare industries.

Key Market Players of Antibody Drug Conjugates Industry:

The veterinary electrosurgery market is a consolidated market, the prominent players in the global market include Medtronic (Ireland), B. Braun (Germany), Integra LifeSciences (US), Olympus Corporation (Japan), Covetrus, Inc. (US), Symmetry Surgical, Inc. (US), Avante Animal Health (DRE Veterinary) (US), Summit Hill Laboratories (US), Burtons Medical Equipment Limited (UK), Eickemeyer (Germany), KLS Martin (Germany), Macan Manufacturing (US), XcelLance Medical Technologies Pvt. Ltd. (India), Alsa Apparecchi Medicali SRL (Italy), and Kentamed Ltd. (Europe).

Get 10% Free Customization on this Report: https://www.marketsandmarkets.com/requestCustomizationNew.asp?id=141714652

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Veterinary Electrosurgery Market worth $120 million by 2028 | Medtronic (Ireland), B. Braun (Germany), Integra LifeSciences (US), Olympus Corporation (Japan), Covetrus, Inc. (US)

Wound Care Market worth $28.6 billion | MarketsandMarkets

“Wound Care Market in terms of revenue was estimated to be worth $21.5 billion in 2023 and is poised to reach $28.6 billion by 2028, growing at a CAGR of 5.9% from 2023 to 2028 according to a new report by MarketsandMarkets™.”

The wound care industry is poised for significant advancements in the near future, driven by a combination of innovative technologies, increased awareness of wound management, and an aging population.

Wound Care Market in terms of revenue was estimated to be worth $21.5 billion in 2023 and is poised to reach $28.6 billion by 2028, growing at a CAGR of 5.9% from 2023 to 2028 according to a new report by MarketsandMarkets™. Growing preference for addressing diseases and health conditions that affect wound healing capabilities, along with the increasing prevalence of conditions like diabetes and obesity, are significant factors driving the wound care market. These conditions often lead to chronic wounds, necessitating advanced wound care solutions. Moreover, emerging economies such as India and Japan are presenting lucrative opportunities for companies operating in the wound care market. The rising awareness about advanced wound care products and an expanding healthcare infrastructure in these regions contribute to the market’s growth potential, attracting both local and international players to invest and expand their presence.

Download an Illustrative overview: https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=371

The advanced wound care products segment accounted for the largest share of the wound care market, by product segment, in 2022.

The wound care market is categorized into three main product segments: advanced wound care products, surgical wound care products, and traditional wound care products. In this market, the advanced wound care products segment held the largest share in 2022. The prevalence of deteriorating health conditions, particularly those directly affecting wound healing like diabetes, has significantly contributed to the dominance of this segment. Patients with conditions like diabetes often experience challenges in wound healing, driving the demand for advanced wound care products to effectively manage and treat such wounds.

Diabetic foot ulcers segment to register the highest growth rate during the forecast period.

The wound care market is categorized into various wound types, including surgical & traumatic wounds, burns, diabetic foot ulcers, pressure ulcers, venous leg ulcers, and other chronic wounds. Among these, the diabetic foot ulcers segment held the highest growth rate in 2022. The primary factor contributing to the substantial share of this segment was the increasing incidence of diabetes. Diabetes often leads to complications and slower wound healing, necessitating wound care products and treatments, thereby driving the demand within this segment.

The hospitals and clinics accounted for the largest share of the wound care market, by end users segment, in 2022.

The wound care market is segmented based on end users into hospitals and clinics, long-term patient care, home care settings, and other end users. The largest share was attributed to the hospitals and clinics segment in 2022. This dominance can primarily be attributed to the increase in cases of health conditions, surgeries, and burn injuries, necessitating comprehensive wound care and treatments, often administered within hospital and clinic settings. The demand for wound care products and services in these healthcare facilities drove the substantial market share of this segment.

North America is the largest regional market for wound care market.

The wound care market is segmented into five major regions: North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa. Among these regions, North America held the largest market share in the wound care market in 2022. A significant share in North America can be attributed to the increasing emphasis on the development of chronic wound management solutions and a strong focus on improving health conditions, particularly related to chronic diseases like diabetes. These factors drove the demand for advanced wound care products and propelled the growth of the wound care market in the region.

Request Sample Pages: https://www.marketsandmarkets.com/requestsampleNew.asp?id=371

Key Market Players of Antibody Drug Conjugates Industry:

The major players operating in this market are 3M Company (US), Smith & Nephew PLC (UK), Cardinal Health (US), Medtronic PLC (Ireland), B. Braun Melsungen AG (Germany), Baxter International, Inc. (US), Mölnlycke Health Care AB (Sweden), Convatec Group (UK), Paul Hartmann AG (Germany), Coloplast A/S (Denmark), Organogenesis Holdings Inc. (US), MiMedx Group, Inc. (US), Integra Life Sciences Holdings Corporation (US), Bioventus (US), Zimmer Biomet Holdings, Inc. (US), Ethicon, Inc. (US), DeRoyal Industries (US), Kerecis (Iceland), Acell (US), Lohmann & Rauscher GmbH & Co. KG (Germany), Medela Ag (Switzerland), Talley Group (UK), Welcare Industries SPA (Italy), Wuhan VSD Medical Science & Technology Co. Ltd. (China), Pensar Medical (US), Haromed BVBA (Belgium), DermaRite Industries LLC (US), Medline Industries, Inc. (US), Advancis Medical LLC (UK) and Mil Laboratories Pvt. Ltd. (India).

Recent Developments:

In January 2023, Convatec Group (UK) launched ConvaFoam, which can be used on a spectrum of wound types at any stage of the wound journey, making it the simple dressing choice for wound management and skin protection.
In September 2022, MiMedx Group, Inc. (US) launched of AMNIOEFFECT, a tri-layer PURION processed human tissue allograft consisting of the amnion, intermediate, and chorion membrane layers of the placenta.
In April 2021, 3M Company launched 3M Spunlace Extended Wear Adhesive Tape on Liner, 4576. It has a longer wear time of 21 days that provides user compliance and health and economic benefits.
In May 2021, Smith & Nephew launched ARIA Home PT, a remote physical therapy product as part of the ARIA suite of solutions.
In March 2020, Cardinal Health launched surgical drape that features Avery Dennison’s patented BeneHold CHG adhesive technology, which helps reduce the risk of surgical site contamination.

Get 10% Free Customization on this Report: https://www.marketsandmarkets.com/requestCustomizationNew.asp?id=371

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Wound Care Market worth $28.6 billion | MarketsandMarkets

Take a Knee Launches New Veteran Support Organization with Mission to Transform Lives

The nonprofit “Take a Knee” aims to address the fundamental needs of National Heroes.

DeAngelo Jelks, a veteran passionate about supporting his fellow servicemen and women, has announced the establishment of a groundbreaking nonprofit organization, “Take a Knee.” Take a Knee understands that even the strongest citizens can become society’s most fragile, when they have needs that aren’t addressed. The new nonprofit is stepping up to meet this challenge and help veterans and their families.

“Whenever the solution is that ‘someone must change things,’ there is no time to wait around. That someone will always be me,” commented DeAngelo Jelks, founder of the nonprofit, who is clearly passionate about this critical task.

Take a Knee provides mental health education and support to post-war veterans at no cost to them. It helps heroes hit the reset button on key relationships, and overcome challenges like suicidal ideation, depression, social isolation, divorce, and others.

Take a Knee offers three days of ‘still motion.’ A space for heroes to heal one another.

To support this noble cause, Take a Knee is actively seeking additional funding to ensure that its programs are offered free of charge to veteran participants. Donations can be made through their fundraising link here.

Take a Knee is not just a veteran-run organization but also promotes minority participation, creating a diverse and inclusive platform for those who have served their country.

For those interested in further engagement, Take a Knee encourages the purchase of the book titled “The 4-Hour Fix-It Plan,” available on Amazon. Authored by DeAngelo Jelks, a veteran and founder of Take a Knee, the book delves into the often-unspoken mental health challenges. It goes beyond the surface, tackling issues many individuals silently grapple with. The 4-Hour Fix-It Plan is a guide to empower readers to navigate and overcome trauma, fear, pain, guilt, and anger, which are often rooted in experiences dating back to early childhood.

The book challenges readers to move beyond the facade of happiness, offering practical tools for self-reflection and healing. It is an ideal read for those living with repressed emotions and for family members seeking a deeper understanding of their loved ones.

Take a Knee invites everyone to join in their mission to support and uplift the lives of our national heroes. Together, we can make a difference in the well-being of those who have sacrificed so much for our freedom.

Connect with Take a Knee on its official Facebook and website at www.TakeAKneeus.org.

Media Contact
Company Name: Take a Knee
Contact Person: DeAngelo Jelks
Email: Send Email
Phone: 423-314-9874
Country: United States
Website: https://www.takeakneeus.org

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Take a Knee Launches New Veteran Support Organization with Mission to Transform Lives